The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine
暂无分享,去创建一个
Tinghui Yu | Meijuan Li | Y. Hu | Yun-Fu Hu | Meijuan Li | Tinghui Yu
[1] Daniel J Sargent,et al. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Shanti Gomatam,et al. Evaluation of Heart Failure Biomarker Tests: A Survey of Statistical Considerations , 2013, Journal of Cardiovascular Translational Research.
[3] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[4] Wendy R. Sanhai,et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.
[5] S. Chow,et al. Inference on treatment effects for targeted clinical trials under enrichment design , 2009, Pharmaceutical statistics.
[6] Meijuan Li. Statistical Consideration and Challenges in Bridging Study of Personalized Medicine , 2015, Journal of biopharmaceutical statistics.
[7] Sid E O'Bryant,et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. , 2008, Archives of neurology.
[8] J. Haines,et al. Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .
[9] Clifford R Jack,et al. Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.
[10] Margaret A. Pericak-Vance,et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .
[11] K Y Young,et al. The efficiency of clinical trial designs for predictive biomarker validation , 2010, Clinical trials.
[12] A. Fagan,et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.